EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Idorsia partners with Antares to develop a self-administered drug-device product for selatogrel, a P2Y12 receptor antagonist in development in acute myocardial infarction. Release 

> Azeria Therapeutics raised £32 million ($41 million) to advance an estrogen receptor positive breast cancer drug. Syncona provided most of the money. Statement 

> The FDA granted orphan drug designation to ProQR Therapeutics’ QR-1123 in autosomal dominant retinitis pigmentosa. Release 

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

> Galapagos confirmed the interim futility analysis for its idiopathic pulmonary fibrosis phase 3 is likely to take place early in 2021. The target is later than analysts at Jefferies hoped. Webcast

> Zealand Pharma delayed the readout from its phase 3 glepaglutide program to the first half of 2021. The target slipped from late 2020 due to delays in the activation of U.K. and U.S. trial sites. Statement 

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.